KMT2A inhibitors can potentially be used to treat other KMT2A aberrant malignancies e.g. KMT2A-PTD and KMT2A-a leukemias, which are in desperate need of improved therapies due to their dismal prognosis (42, 85). This evidence concerns the gene KMT2A and Bjornstad syndrome.